4-(4-Aminophenyl)morpholin-3-One CAS 438056-69-0 Purity ≥99.0% (HPLC) Rivaroxaban Intermediate Factory

Chemical Name: 4-(4-Aminophenyl)morpholin-3-One CAS: 438056-69-0 Appearance: White to Off-White Powder Purity: ≥99.0% (HPLC) Intermediate of Rivaroxaban (CAS: 366789-02-8) in the treatment of Venous Thromboembolism(VTE) Inquiry: alvin@ruifuchem.com

Products Details

Chemical Properties:

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.Manufacturer Supply Rivaroxaban Related Intermediates: (S)-(+)-Glycidyl Phthalimide CAS 161596-47-0 4-(4-Aminophenyl)morpholin-3-one CAS 438056-69-0 Rivaroxaban Intermediate CAS 446292-07-5 5-Chlorothiophene-2-Carboxylic Acid CAS 24065-33-6 5-Chlorothiophene-2-Carbonyl Chloride CAS 42518-98-9 Rivaroxaban API CAS 366789-02-8
Item Specifications
Appearance White to Light Yellow or Light Brown Crystalline Powder
Purity / Analysis Method ≥99.0% (HPLC)
Melting Point 165.0~175.0°C
Identification HNMR
Moisture (K.F) ≤1.0%
Loss on Drying ≤0.50%
Residue on lgnition  ≤0.10%
Max Single Impurity ≤0.50%
Total Impurities ≤1.5%
Test Standard Enterprise Standard
Usage Rivaroxaban (CAS: 366789-02-8) Intermediate 
4-(4-Aminophenyl)morpholin-3-one CAS: 438056-69-0 Synthesis Route 4-(4-Aminophenyl)morpholin-3-one CAS 438056-69-0

Description:

Specifications:

Package & Storage:

Chemical Name 4-(4-Aminophenyl)morpholin-3-One 
CAS Number 438056-69-0
CAT Number RF-PI129
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C10H12N2O2
Molecular Weight 192.21
Brand Ruifu Chemical

Advantages:

FAQ:

Application:

Ruifu Chemical is the leading manufacturer and supplier of 4-(4-Aminophenyl)morpholin-3-one (CAS: 438056-69-0) with high quality, it is an intermediate in the synthesis of Rivaroxaban (CAS: 366789-02-8). Rivaroxaban is a pure (S)-enantiomer. Rivaroxaban (BAY 59-7939) is an oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of venous thromboembolism (VTE).

Contact us

Please feel free to give your inquiry in the form below We will reply you in 24 hours